Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73:233–54.
Clinton SK, Giovannucci EL, Hursting SD. The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions. J Nutr. 2020;150:663–71.
Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72:338–44.
Swartjes H, Brouwer NPM, de Nes LCF, van Erning FN, Verhoeven RHA, Vissers PAJ, et al. Incidence, treatment and relative survival of early-onset colorectal cancer in the Netherlands since 1989. Eur J Cancer. 2022;166:134–44.
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394:1467–80.
Tauriello DVF, Calon A, Lonardo E, Batlle E. Determinants of metastatic competency in colorectal cancer. Mol Oncol. 2017;11:97–119.
Akgül Ö. Role of surgery in colorectal cancer liver metastases. World J Gastroenterol. 2014;20:6113–6122.
Al Bandar MH, Kim NK. Current status and future perspectives on treatment of liver metastasis in colorectal cancer. Oncol Rep. 2017;37:2553–64.
Takahashi H, Berber E. Role of thermal ablation in the management of colorectal liver metastasis. Hepatobiliary Surg Nutr. 2020;9:49–58.
de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374–403.
Bejarano L, Jordāo MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11:933–59.
Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31–46.
Biffi G, Oni TE, Spielman B, Hao Y, Elyada E, Park Y, et al. IL1-induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 2019;9:282–301.
Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174–86.
Huang H, Wang Z, Zhang Y, Pradhan RN, Ganguly D, Chandra R, et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022;40:656–73.e7.
Zhang X, Zheng S, Hu C, Li G, Lin H, Xia R, et al. Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. Oncogene. 2022;41:2372–89.
Özdemir BernaC, Pentcheva-Hoang T, Carstens JulienneL, Zheng X, Wu C-C, Simpson TylerR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25:719–34.
Vitorino M, Eiriz I, Tomás TC, Vicente R, Mendes A, Freitas AR, et al. Association of tumor-infiltrating lymphocytes with survival in stages II and III colorectal cancer. Cureus. 2022;14:e31144.
Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2021;22:209–23.
Mecham RP, Gibson MA. The microfibril-associated glycoproteins (MAGPs) and the microfibrillar niche. Matrix Biol. 2015;47:13–33.
Segade F, Trask BC, Broekelmann TJ, Pierce RA, Mecham RP. Identification of a matrix-binding domain in MAGP1 and MAGP2 and intracellular localization of alternative splice forms. J Biol Chem. 2002;277:11050–7.
Segade F, Suganuma N, Mychaleckyj JC, Mecham RP. The intracellular form of human MAGP1 elicits a complex and specific transcriptional response. Int J Biochem Cell Biol. 2007;39:2303–13.
Zhao LQ, Sun W, Zhang P, Gao W, Fang CY, Zheng AW. MFAP2 aggravates tumor progression through activating FOXM1/β-catenin-mediated glycolysis in ovarian cancer. Kaohsiung J Med Sci. 2022;38:772–80.
Yao L-w, Wu L-l, Zhang L-h, Zhou W, Wu L, He K, et al. MFAP2 is overexpressed in gastric cancer and promotes motility via the MFAP2/integrin α5β1/FAK/ERK pathway. Oncogenesis. 2020;9:17.
Zhu X, Cheng Y, Wu F, Sun H, Zheng W, Jiang W, et al. MFAP2 promotes the proliferation of cancer cells and is associated with a poor prognosis in hepatocellular carcinoma. Technol Cancer Res Treat. 2020;19:1533033820977524.
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. J Cereb Blood Flow Metab. 2020;40:1769–77.
Niu N, Shen X, Wang Z, Chen Y, Weng Y, Yu F, et al. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Cancer Cell. 2024;42:869–84.e9.
Liu M, Ren Y, Zhou Z, Yang J, Shi X, Cai Y, et al. The crosstalk between macrophages and cancer cells potentiates pancreatic cancer cachexia. Cancer Cell. 2024;42:885–903.e4.
Zheng H, An M, Luo Y, Diao X, Zhong W, Pang M, et al. PDGFRα+ ITGA11+ fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplay. Cancer Cell. 2024;42:682–700.e12.
Sreekumar A, Lu M, Choudhury B, Pan T-c, Pant DK, Lawrence-Paul MR, et al. B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling. Cancer Cell. 2024;42:52–69.e7.
Paluch EK, Aspalter IM, Sixt M. Focal adhesion-independent cell migration. Annu Rev Cell Dev Biol. 2016;32:469–90.
Ringer P, Colo G, Fassler R, Grashoff C. Sensing the mechano-chemical properties of the extracellular matrix. Matrix Biol. 2017;64:6–16.
Humphries MJ. Integrin Structure. Biochem Soc Trans. 2000;28:311–40.
Zhou J, Yi Q, Tang L. The roles of nuclear focal adhesion kinase (FAK) on cancer: a focused review. J Exp Clin Cancer Res. 2019;38:250.
Sun J, Luo Q, Liu L, Song G. Low-level shear stress promotes migration of liver cancer stem cells via the FAK-ERK1/2 signalling pathway. Cancer Lett. 2018;427:1–8.
Lu X, Han J, Xu X, Xu J, Liu L, Huang Y, et al. PGE2 promotes the migration of mesenchymal stem cells through the activation of FAK and ERK1/2 pathway. Stem Cells Int. 2017;2017:8178643.
Plotnik JP, Budka JA, Ferris MW, Hollenhorst PC. ETS1 is a genome-wide effector of RAS/ERK signaling in epithelial cells. Nucleic Acids Res. 2014;42:11928–40.
Kabbout M, Dakhlallah D, Sharma S, Bronisz A, Srinivasan R, Piper M, et al. MicroRNA 17-92 cluster mediates ETS1 and ETS2-dependent RAS-oncogenic transformation. PLoS ONE. 2014;9:e100693.
Yang B-S, Hauser CA, Henkel G, Colman MS, Beveren CV, Stacey KJ, et al. Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol. 2023;16:538–47.
Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342:1094–8.
Norlin M, von Bahr S, Bjorkhem I, Wikvall K. On the substrate specificity of human CYP27A1: implications for bile acid and cholestanol formation. J Lipid Res. 2003;44:1515–22.
Voisin M, de Medina P, Mallinger A, Dalenc F, Huc-Claustre E, Leignadier J, et al. Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor. Proc Natl Acad Sci USA. 2017;114:E9346–E55.
Chimento A, Casaburi I, Avena P, Trotta F, De Luca A, Rago V, et al. Cholesterol and its metabolites in tumor growth: therapeutic potential of statins in cancer treatment. Front Endocrinol. 2019;9:807.
Ding X, Zhang W, Li S, Yang H. The role of cholesterol metabolism in cancer. Am J Cancer Res. 2019;9:219–27.
Kloudova A, Guengerich FP, Soucek P. The role of oxysterols in human cancer. Trends Endocrinol Metab. 2017;28:485–96.
Olkkonen VM, Beaslas O, Nissila E. Oxysterols and their cellular effectors. Biomolecules. 2012;2:76–103.
Baek AE, Yu Y-RA, He S, Wardell SE, Chang C-Y, Kwon S, et al. The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun. 2017;8:864.
Huang B, Song BL, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2:132–41.
Kidani Y, Elsaesser H, Hock MB, Vergnes L, Williams KJ, Argus JP, et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat Immunol. 2013;14:489–99.
Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell. 2008;134:97–111.
Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996;383:728–31.
Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 2000;16:459–81.
Kennel KB, Bozlar M, De Valk AF, Greten FR. Cancer-associated fibroblasts in inflammation and antitumor immunity. Clin Cancer Res. 2023;29:1009–16.
Song L, Wang S, Li Q, Lu Y, Yang R, Feng X. Identification and validation of a m5C RNA modification-related gene signature for predicting prognosis and immunotherapeutic efficiency of gastric cancer. J Oncol. 2023;2023:9931419.
Guo P, Dai T, Jin X, Wu H, Qiu S, Tang C, et al. MFAP2 promotes the malignant progression of gastric cancer via activating the PI3K/AKT signaling pathway. J Recept Signal Transduct. 2025;45:150–9.
Jiang S, Zheng Z, Yuan B, Yan R, Yao Q, Chen H, et al. MFAP2 induces epithelial-mesenchymal transformation of osteosarcoma cells by activating the Notch1 pathway. Transl Cancer Res. 2024;13:2847.
Chu Z, Pan P, Qi S, Fang S, Zhang Z, Cheng Z, et al. MFAP2 promotes the progress of esophageal squamous cell carcinoma by enhancing PTGS2 signaling. J Cancer. 2025;16:2846.
Zhang H, Shen S, Feng C, Chen G, Wang X. MFAP2 promotes the progression of oral squamous cell carcinoma by activating the Wnt/β-catenin signaling pathway through autophagy: MFAP2 and autophagy-induced OSCC progression. Acta Biochim Biophys Sin. 2023;55:1445.
Wei R, Song J, Liu X, Huo S, Liu C, Liu X. Immunosuppressive MFAP2+ cancer associated fibroblasts conferred unfavorable prognosis and therapeutic resistance in gastric cancer. Cell Oncol. 2024;47:55–68.
Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer cell. 2019;35:347–67.
Park EJ, Myint PK, Ito A, Appiah MG, Darkwah S, Kawamoto E, et al. Integrin-ligand interactions in inflammation, cancer, and metabolic disease: insights into the multifaceted roles of an emerging ligand irisin. Front Cell Dev Biol. 2020;8:588066.
Wong P-P, Muñoz-Félix JM, Hijazi M, Kim H, Robinson SD, De Luxán-Delgado B, et al. Cancer burden is controlled by mural cell-β3-integrin regulated crosstalk with tumor cells. Cell. 2020;181:1346–63.e21.
Mezu-Ndubuisi OJ, Maheshwari A. The role of integrins in inflammation and angiogenesis. Pediatr Res. 2021;89:1619–26.
Kamali Zonouzi S, Pezeshki P, Razi S, Rezaei N. Cancer-associated fibroblasts in colorectal cancer. Clin Transl Oncol. 2022;24:757–69.
Deng Y, Huang X, Yang Y, Zhang Y, Zeng B, Bao Y, et al. MFAP2 upregulation promotes ESCC metastasis via FAK–AKT signaling pathway. FASEB J. 2024;38:e70266.